Evidence map›Paper›PMID 40269808›Full record

SynthesisBMC pulmonary medicine2025

Stereotactic body radiation therapy and thermal ablation for treatment of patients with pulmonary metastases: a systematic literature review and meta-analysis.

Paul Laeseke, Calvin Ng, Nicole Ferko, Andrada Naghi, George W J Wright, Di Wang, Alyshia Laidlaw, Iftekhar Kalsekar, Tony Amos, Balaji Laxmanan and 4 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Paul LaesekeRadiology, University of Wisconsin, 600 Highland Avenue, Madison, WI, 53792, USA. plaeseke@wisc.edu.
Calvin NgDepartment of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, NT, Hong Kong, China.
Nicole FerkoEVERSANA, Burlington, ON, Canada.
Andrada NaghiEVERSANA, Burlington, ON, Canada.
George W J WrightEVERSANA, Burlington, ON, Canada.
Di WangEVERSANA, Burlington, ON, Canada.
Alyshia LaidlawEVERSANA, Burlington, ON, Canada.
Iftekhar KalsekarLung Cancer Initiative, Johnson & Johnson, New Brunswick, NJ, USA.
Tony AmosLung Cancer Initiative, Johnson & Johnson, New Brunswick, NJ, USA.
Balaji LaxmananLung Cancer Initiative, Johnson & Johnson, New Brunswick, NJ, USA.
Sudip K GhoshHealth Economics and Market Access, Johnson & Johnson, Cincinnati, OH, USA.
Meijia ZhouMedical Technology Epidemiology and Real World Data Science, Johnson & Johnson, New Brunswick, NJ, USA.
Philippe SzaparyLung Cancer Initiative, Johnson & Johnson, New Brunswick, NJ, USA.
Michael PritchettPulmonary and Critical Care Medicine, FirstHealth Moore Regional Hospital, and Pinehurst Medical Clinic, Pinehurst, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare local tumor progression (LTP) and overall survival (OS) after image-guided thermal ablation (IGTA; microwave/radiofrequency ablation) versus stereotactic body radiation therapy (SBRT) in patients with pulmonary metastases.

methodsA systematic literature review was performed to capture studies that used IGTA or SBRT for patients with pulmonary metastases and studies that reported one, two, and threeyear LTP/OS were included. Patients with pulmonary metastases, and a subgroup with metastases from colorectal or renal cell carcinoma, or sarcoma (termed subgroup) which are considered more radioresistant, were analyzed. Single-arm pooled analyses, univariable, and multivariable random-effects meta-regressions were conducted to compare LTP and OS between IGTA and SBRT treated patients.

resultsAnalyses included 3,264 IGTA and 5,486 SBRT patients. IGTA patients with pulmonary metastases had higher LTP than SBRT patients at one year, 13% and 9% respectively. At two years, the LTP for IGTA patients was 14% compared to 16% for SBRT patients. Three-year LTP remained lower for IGTA patients compared to SBRT patients (14% and 22% respectively). In the subgroup, SBRT patients had higher LTP than IGTA patients across all timepoints. OS was similar across analyses/subgroups in the single-arm pooled analyses. The multivariable analyses showed that SBRT was associated with significantly lower OS at one year; however nonsignificant differences were observed at years two and three.

conclusionsIn patients with pulmonary metastases, IGTA had lower LTP than SBRT at later timepoints. In patients with colorectal, renal cell carcinoma, or sarcoma pulmonary metastases, LTP was similar to overall LTP for IGTA, while it was higher for SBRT.

Indexed as

Lung NeoplasmsRadiosurgeryCarcinoma, Renal CellColorectal NeoplasmsDisease ProgressionHumansKidney NeoplasmsSarcomaMeta-analysisMeta regressionMicrowave ablationOligometastasesRadiofrequency ablationRadioresistantStereotactic body radiation therapySystematic literature review

Identifiers

PMID40269808
PMCPMC12016196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.